Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Sac-TMT plus pembrolizumab-based neoadjuvant therapy versus standard chemotherapy plus pembrolizumab in high-risk early breast cancer
MOH_2025-06-18_014146Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Merck & Co. Started Jun 2025; status: recruiting.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on MOH_2025-06-18_014146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-18_014146.